During the last session, Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s traded shares were 28.47 million, with the beta value of the company hitting 0.85. At the end of the trading day, the stock’s price was $8.50, reflecting an intraday gain of 1.92% or $0.16. The 52-week high for the RXRX share is $15.74, that puts it down -85.18 from that peak though still a striking 34.12% gain since the share price plummeted to a 52-week low of $5.60. The company’s market capitalization is $3.32B, and the average trade volume was 17.41 million shares over the past three months.
Recursion Pharmaceuticals Inc (RXRX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.43. RXRX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.42.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
Recursion Pharmaceuticals Inc (RXRX) registered a 1.92% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.92% in intraday trading to $8.50, hitting a weekly high. The stock’s 5-day price performance is 17.40%, and it has moved by 34.49% in 30 days. Based on these gigs, the overall price performance for the year is -22.30%.
The consensus price target of analysts on Wall Street is $11, which implies an increase of 22.73% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $12 respectively. As a result, RXRX is trading at a discount of -41.18% off the target high and 29.41% off the low.
Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts
In the rating firms’ projections, revenue will increase 52.11% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 19.04M as predicted by 7 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 12M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 10.89M and 13.79M respectively. In this case, analysts expect current quarter sales to grow by 74.85% and then drop by -13.01% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -43.41%. While earnings are projected to return 2.61% in 2025, the next five years will return 4.49% per annum.
RXRX Dividends
Recursion Pharmaceuticals Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 26.59 million shares, is of BAILLIE GIFFORD & CO’s that is approximately 11.266% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $199.42 million.
